BMS-564929 is an agonist of androgen receptor (AR, Ki of 2.11±0.16 nM).

BMS-564929 is more than 1000-fold selective for AR vs. estrogen receptors (ER) α and β, glucocorticoid receptor (GR), and mineralocorticoid receptor (MR), and approximately 400-fold selective vs. BMS-564929 shows no measurable activity in functional transactivation assays with ERα/β, GR, MR, or PR at concentrations up to 30 μM[1]. BMS-564929 exhibits a potency (EC50, calculated as the concentration at which 50% of the maximum stimulatory effect of DHT is achieved) of 0.44±0.03 nM in the C2C12 myoblast cell line. In the PEC cell line, the EC50 for BMS-564929 is 8.66±0.22 nM. progesterone receptor (PR).

BMS-564929 is more than 200 times more potent in stimulation of muscle and 80 times more selective for muscle vs. prostate, compared with T propionate (TP) in the same model[1]. BMS-564929 (p.o.) shows substantially more potent activity in the levator ani, exhibiting an ED50 of 0.0009 mg/kg in the levator ani and an ED50 of 0.14 mg/kg in the prostate; a net 160-fold selectivity for muscle vs. prostate, in sexually mature, castrated male rats, a well-characterized animal model. Approximately 100% muscle stimulation is achieved at 0.1 mg/kg, reaching greater than 125% stimulation at 0.3 and 1 mg/kg.

627530-84-1

C14H12ClN3O3

305.72

DMSO:50 mg/mL (163.55 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years